{"entity":{"id":"tqb3909","kind":"drug","name":"TQB3909","aka":[],"tldr":"TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer.","summary":"TQB3909 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in metastatic cancer. Described in the registry record as a tqb3909 is a protein inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of TQB3909","url":"https://clinicaltrials.gov/search?intr=TQB3909"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07011186"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"TQB3909","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a tqb3909 is a protein inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tqb3909/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","route":"/trials/nct07011186/"}]}}